Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Interest & Investment Income (2021 - 2025)

Janux Therapeutics has reported Interest & Investment Income over the past 5 years, most recently at $10.5 million for Q4 2025.

  • Quarterly Interest & Investment Income rose 18.73% to $10.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.0 million through Dec 2025, up 47.53% year-over-year, with the annual reading at $44.0 million for FY2025, 47.53% up from the prior year.
  • Interest & Investment Income was $10.5 million for Q4 2025 at Janux Therapeutics, down from $10.9 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $11.4 million in Q1 2025 and troughed at $46000.0 in Q2 2021.
  • The 5-year median for Interest & Investment Income is $4.2 million (2023), against an average of $4.9 million.
  • Year-over-year, Interest & Investment Income surged 2874.32% in 2022 and then rose 18.73% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at $74000.0 in 2021, then surged by 2874.32% to $2.2 million in 2022, then surged by 98.96% to $4.4 million in 2023, then surged by 101.1% to $8.8 million in 2024, then rose by 18.73% to $10.5 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Interest & Investment Income are $10.5 million (Q4 2025), $10.9 million (Q3 2025), and $11.3 million (Q2 2025).